Sustainable complete remission in recurrence yolk sac tumor patient treated with tandem high-dose chemotherapy and autologous stem cell

A 21-year-old lady diagnosed with Stage 3 ovarian yolk sac tumor (YST) underwent primary cytoreductive fertility sparing surgery, followed by conventional courses of platinum-based chemotherapy and etoposide. Recurrence at cul-da-sac was noted after a short period of remission and secondary debulking performed followed by four cycles of conventional chemotherapy. The patient’s disease progressed despite courses of treatments. A joint team management including a hematologist was commenced following the failure of conventional chemotherapies. Two cycles of high-dose chemotherapy (HDCT) with ifosfamide/cisplatin/etoposide (ICE) regimen, followed by autologous stem cell transplantation (ASCT) were given. With this salvage treatment, she remained in complete remission and disease-free for more than 30 months, while maintaining her reproductive function. These approaches appear to be effective as a salvage treatment in selected cases of patients with ovarian germ cell tumor, especially those who failed primary conventional chemotherapy.

High-dose chemotherapy; Germ cell tumor; Autologous stem cell.

[1] Dallenbach P., Bonnefoi H., Pelte M.F., Vlastos G.: “Yolk sac tumours of the ovary: an update”. Eur. J. Surg. Oncol., 2006, 32, 1063.

[2] Pestasides D., Pectasides E., Kassanos D.: “Germ cell tumor of ovary”. Cancer Treat. Rev., 2008, 34, 427.

[3] El-Helw L., Coleman R.E.: “Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours’. Cancer Treat. Reviews, 2005, 31, 197.

[4] de La Motte Rouge T., Pautier P., Rey A., Duvillard P., Kerbrat P., Troalen F. et al.: “Prognostic factors in women treated for ovarian yolk sac tumour: a retrospective analysis of 84 cases”. Eur. J. Cancer, 2011, 47, 175. Epub 2010 Sep. 28.

[5] Li J., Yang W., Wu X.: “Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients”. Gynecol. Oncol., 2007, 105, 769.

[6] Mitchell P.L., Al-Nasiri N., A’Hern R., Fisher C., Horwich A., Pinkerton C.R. et al.: “Treatment of nondysgerminomatous ovarian germ cell tumors: an analysis of 69 cases”. Cancer, 1999, 85, 2232.

[7] Connolly R.M., McCaffrey J.A.: “High-dose chemotherapy plus stem cell transplantation in advanced germ cell cancer: a review”. Eur. Urol., 2009, 56, 57.

[8] Rick O., Siegert W., Beyer J.: “Chemotherapy in patients with metastatic or relapsed germ-cell tumours”. Cancer Treat. Rev., 2001, 27, 283.

[9] Kondagunta G.V., Bacik J., Sheinfeld J., Bajorin D., Bains M., Reich L. et al.: “Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors”. J. Clin. Oncol., 2007, 25, 85.

[10] Einhorn L.H., Williams S.D., Chamness A. et al.: “High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors”. NEJM, 2007, 357, 340.